Detection of liver metastases using gadoxetic-enhanced dynamic and 10- and 20-minute delayed phase MR imaging

Journal of Magnetic Resonance Imaging

Volumn 35, Issue 3, 2012, Pages 635-643

  Jeong, Hyeon Tae ^a   Kim, Myeong Jin ^a   Park, Mi Suk ^a   Choi, Jin Young ^a   Choi, Jin Sub ^a   Kim, Kyung Sik ^a   Choi, Gi Hong ^a   Shin, Sang Joon ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

diagnosis; diagnostic accuracy; liver neoplasm; liver specific contrast agents; magnetic resonance imaging (MRI)

Indexed keywords

ANTINEOPLASTIC AGENT; GADOXETIC ACID;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SIZE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIGESTIVE SYSTEM CANCER; FEMALE; HUMAN; IMAGE ANALYSIS; LIVER METASTASIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SIGNAL NOISE RATIO;

ANALYSIS OF VARIANCE; COMBINED MODALITY THERAPY; CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84863126799     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22880     Document Type: Article

References (45)

1. Liu PS, Francis IR,. Hepatic imaging for metastatic disease. Cancer J 2010; 16: 93-102.
2. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG,. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-135.
3. Niekel MC, Bipat S, Stoker J,. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-684.
4. Ward J,. New MR techniques for the detection of liver metastases. Cancer Imaging 2006; 6: 33-42.
5. Semelka RC, Cance WG, Marcos HB, Mauro MA,. Liver metastases: comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999; 213: 86-91. (Pubitemid 29470410)
6. Floriani I, Torri V, Rulli E, et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31.
7. Shimada K, Isoda H, Hirokawa Y, Arizono S, Shibata T, Togashi K,. Comparison of gadolinium-EOB-DTPA-enhanced and diffusion-weighted liver MRI for detection of small hepatic metastases. Eur Radiol 2010; 20: 2690-2698.
8. Lowenthal D, Zeile M, Lim WY, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011; 21: 832-840.
9. Kim YK, Lee YH, Kwak HS, Kim CS, Han YM,. Detection of liver metastases: gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran- enhanced MR imaging. Eur J Radiol 2010; 73: 131-136.
10. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO,. MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent Gd-EOB-DTPA. Magn Reson Med Sci 2007; 6: 43-52.
11. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY,. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010; 255: 459-466.
12. Lowenthal D, Zeile M, Lim WY, et al. Detection and characterisation of focal liver lesions in colorectal carcinoma patients: comparison of diffusion-weighted and Gd-EOB-DTPA enhanced MR imaging. Eur Radiol 2011; 21: 832-840.
13. Hammerstingl R, Huppertz A, Breuer J, et al. Diagnostic efficacy of gadoxetic acid (Primovist)-enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 2008; 18: 457-467. (Pubitemid 351248177)
14. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996; 200: 59-67. (Pubitemid 26197732)
15. Stern W, Schick F, Kopp AF, et al. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA. Acta Radiol 2000; 41: 255-262.
16. Reimer P, Rummeny EJ, Shamsi K, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology 1996; 199: 177-183. (Pubitemid 26098637)
17. Hamm B, Staks T, Muhler A, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 1995; 195: 785-792.
18. Primovist [package insrt]. Berlin, Germany: Bayer Schering Pharma; 2004.
19. Huppertz A, Haraida S, Kraus A, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. (Pubitemid 40139918)
20. Reimer P, Rummeny EJ, Daldrup HE, et al. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: preliminary results with dynamic MR imaging. Eur Radiol 1997; 7: 275-280. (Pubitemid 127538595)
21. Motosugi U, Ichikawa T, Tominaga L, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol 2009; 19: 2623-2629.
22. Fischer L, Thorn M, Neumann JO, et al. The segments of the hepatic veins-is there a spatial correlation to the Couinaud liver segments? Eur J Radiol 2005; 53: 245-255. (Pubitemid 40143586)
23. Mori K, Takahashi N, Hiratsuka M, et al. Detection of hepatic metastases using ferucarbotran-enhanced MR imaging: feasibility and diagnostic accuracy of three-dimensional sensitivity-encoding water-excitation multishot echo-planar sequence (3D-SWEEP). J Magn Reson Imaging 2006; 24: 1110-1116. (Pubitemid 44660056)
24. Furuhata T, Okita K, Tsuruma T, et al. Efficacy of SPIO-MR imaging in the diagnosis of liver metastases from colorectal carcinomas. Dig Surg 2003; 20: 321-325. (Pubitemid 36819026)
25. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH,. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005; 15: 220-228.
26. Rappeport ED, Loft A,. Liver metastases from colorectal cancer: imaging with superparamagnetic iron oxide (SPIO)-enhanced MR imaging, computed tomography and positron emission tomography. Abdom Imaging 2007; 32: 624-634. (Pubitemid 47594251)
27. Robinson PJ,. Imaging liver metastases: current limitations and future prospects. Br J Radiol 2000; 73: 234-241. (Pubitemid 30192793)
28. Malik HZ, Gomez D, Wong V, et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol 2007; 33: 1003-1009. (Pubitemid 47408735)
29. Huppertz A, Balzer T, Blakeborough A, et al. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275. (Pubitemid 37549812)
30. Petersein J, Spinazzi A, Giovagnoni A, et al. Focal liver lesions: evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study. Radiology 2000; 215: 727-736. (Pubitemid 30346007)
31. Pirovano G, Vanzulli A, Marti-Bonmati L, et al. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions. AJR Am J Roentgenol 2000; 175: 1111-1120.
32. Choi JY, Choi JS, Kim MJ, et al. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent. J Magn Reson Imaging 2010; 31: 571-578.
33. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010; 31: 356-364.
34. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology 2005; 237: 89-98. (Pubitemid 41346150)
35. Halavaara J, Breuer J, Ayuso C, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT-a multicenter trial. J Comput Assist Tomogr 2006; 30: 345-354. (Pubitemid 43922248)
36. Choi JS, Kim MJ, Choi JY, Park MS, Lim JS, Kim KW,. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 2010; 20: 1052-1060.
37. Kim YK, Kwak HS, Kim CS, Han YM,. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009; 30: 437-443.
38. Cruite I, Schroeder M, Merkle EM, Sirlin CB,. Gadoxetate disodium-enhanced MRI of the liver. Part 2. Protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol 2010; 195: 29-41.
39. Ringe KI, Husarik DB, Sirlin CB, Merkle EM,. Gadoxetate disodium-enhanced MRI of the liver. Part 1. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010; 195: 13-28.
40. Arisawa Y, Sutanto-Ward E, Fortunato L, Sigurdson ER,. Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: a regional antiangiogenic therapy. Ann Surg Oncol 1995; 2: 114-120.
41. Abdalla EK, Vauthey JN,. Chemotherapy prior to hepatic resection for colorectal liver metastases: helpful until harmful? Dig Surg 2008; 25: 421-429.
42. Khan AZ, Morris-Stiff G, Makuuchi M,. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J Hepatobiliary Pancreat Surg 2009; 16: 137-144.
43. Kuwatsuru R, Brasch RC, Muhler A, et al. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents. Radiology 1997; 202: 131-138. (Pubitemid 27024118)
44. Choi SB, Song J, Kang CM, et al. Surgical outcome of metachronous hepatic metastases secondary to gastric cancer. Hepatogastroenterology 2010; 57: 29-34.
45. Tsujimoto H, Ichikura T, Ono S, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int 2010; 4: 406-413.